These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 37994574)

  • 1. 1-Benzylimidazole attenuates the stemness of breast cancer cells through partially targeting CYP4Z1.
    Qin H; Zhou Y; Liu H; Yuan Y; Guo Q; Yuan M; Xi T; Zhang Y
    Environ Toxicol; 2024 Mar; 39(3):1505-1520. PubMed ID: 37994574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HET0016 attenuates the stemness of breast cancer cells through targeting CYP4Z1.
    Liu H; Qin H; Zhou Y; Yuan Y; Liu Y; Chen Y; Yang Y; Ni H; Xi T; Zheng L
    Mol Carcinog; 2021 Jun; 60(6):413-426. PubMed ID: 33866606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells.
    Zheng L; Guo Q; Xiang C; Liu S; Jiang Y; Gao L; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Wang Y; Li X; Xi T
    J Hematol Oncol; 2019 Mar; 12(1):23. PubMed ID: 30832689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP4Z1 - A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer.
    Yang X; Hutter M; Goh WWB; Bureik M
    Curr Pharm Des; 2017; 23(14):2060-2064. PubMed ID: 28176668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer.
    Yu W; Chai H; Li Y; Zhao H; Xie X; Zheng H; Wang C; Wang X; Yang G; Cai X; Falck JR; Yang J
    Toxicol Appl Pharmacol; 2012 Oct; 264(1):73-83. PubMed ID: 22841774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient substrate screening and inhibitor testing of human CYP4Z1 using permeabilized recombinant fission yeast.
    Yan Q; Machalz D; Zöllner A; Sorensen EJ; Wolber G; Bureik M
    Biochem Pharmacol; 2017 Dec; 146():174-187. PubMed ID: 28951277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma.
    Rieger MA; Ebner R; Bell DR; Kiessling A; Rohayem J; Schmitz M; Temme A; Rieber EP; Weigle B
    Cancer Res; 2004 Apr; 64(7):2357-64. PubMed ID: 15059886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a Novel Potent CYP4Z1 Inhibitor Attenuating the Stemness of Breast Cancer Cells through Lead Optimization.
    Yuan Y; Yao H; Zhou M; Ma X; Zhou Y; Xu J; Niu M; Yin J; Zheng L; Xu S
    J Med Chem; 2022 Dec; 65(23):15749-15769. PubMed ID: 36414390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of estrogen receptor alpha (ERα) expression in transgenic mice expressing human CYP4Z1.
    Khayeka-Wandabwa C; Zhao J; Pathak JL; Wu H; Bureik M
    Breast Cancer Res Treat; 2022 Jan; 191(2):319-326. PubMed ID: 34725776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome 4Z1 Expression Connotes Unfavorable Prognosis in Ovarian Cancers.
    Al-Saraireh YM; Alshammari FOFO; Satari AO; Al-Mahdy YS; Almuhaisen GH; Abu-Azzam OH; Uwais AN; Abufraijeh SM; Al-Kharabsheh AM; Al-Dalain SM; Al-Qtaitat A; Al-Tarawneh F; Al Shuneigat JM; Al-Sarayreh SA
    Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor.
    Machalz D; Li H; Du W; Sharma S; Liu S; Bureik M; Wolber G
    Eur J Med Chem; 2021 Apr; 215():113255. PubMed ID: 33611185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and Functional Characterization of Breast Cancer-Associated Cytochrome P450 4Z1 in
    McDonald MG; Ray S; Amorosi CJ; Sitko KA; Kowalski JP; Paco L; Nath A; Gallis B; Totah RA; Dunham MJ; Fowler DM; Rettie AE
    Drug Metab Dispos; 2017 Dec; 45(12):1364-1371. PubMed ID: 29018033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. There and Back Again: A Perspective on 20 Years of CYP4Z1.
    Kowalski JP; Rettie AE
    Drug Metab Dispos; 2024 May; 52(6):498-507. PubMed ID: 38604728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.
    Zheng L; Li X; Gu Y; Lv X; Xi T
    Breast Cancer Res Treat; 2015 Feb; 150(1):105-18. PubMed ID: 25701119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP4Z1 3'UTR represses migration of human breast cancer cells.
    Wang B; Zheng L; Chou J; Li C; Zhang Y; Meng X; Xi T
    Biochem Biophys Res Commun; 2016 Sep; 478(2):900-7. PubMed ID: 27520371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The competing endogenous RNA network of CYP4Z1 and pseudogene CYP4Z2P exerts an anti-apoptotic function in breast cancer.
    Li C; Zheng L; Xin Y; Tan Z; Zhang Y; Meng X; Wang Z; Xi T
    FEBS Lett; 2017 Apr; 591(7):991-1000. PubMed ID: 28236635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer.
    Al-Saraireh YM; Alshammari FOFO; Youssef AMM; Al-Sarayra YM; Al-Saraireh RA; Al-Muhaisen GH; Al-Mahdy YS; Al-Kharabsheh AM; Abufraijeh SM; Alrawashdeh HM
    Curr Oncol; 2021 Sep; 28(5):3573-3584. PubMed ID: 34590601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.
    Kowalski JP; McDonald MG; Pelletier RD; Hanenberg H; Wiek C; Rettie AE
    J Med Chem; 2020 May; 63(9):4824-4836. PubMed ID: 32302132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer.
    Zheng L; Li X; Meng X; Chou J; Hu J; Zhang F; Zhang Z; Xing Y; Liu Y; Xi T
    Mol Cell Endocrinol; 2016 May; 427():133-42. PubMed ID: 26980484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans.
    Khayeka-Wandabwa C; Ma X; Cao X; Nunna V; Pathak JL; Bernhardt R; Cai P; Bureik M
    Int Immunopharmacol; 2019 Aug; 73():64-71. PubMed ID: 31082724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.